WallStreetZenWallStreetZen

NASDAQ: TPST
Tempest Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TPST

Based on 2 analysts offering 12 month price targets for Tempest Therapeutics Inc

Min Forecast
$7.00+1.45%
Avg Forecast
$11.50+66.67%
Max Forecast
$16.00+131.88%

Should I buy or sell TPST stock?

Based on 2 analysts offering ratings for Tempest Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TPST's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates TPST as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their TPST stock forecasts and price targets.

TPST stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-03-28

1 of 1

Forecast return on equity

Is TPST forecast to generate an efficient return?

Company
-525.59%
Industry
158.69%
Market
89.3%
TPST's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TPST forecast to generate an efficient return on assets?

Company
-181.92%
Industry
40.47%
TPST is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TPST earnings per share forecast

What is TPST's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$11.59
Avg 2 year Forecast
-$16.02
Avg 3 year Forecast
-$13.33

TPST revenue forecast

What is TPST's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.7M

TPST vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TPST$6.90$11.50+66.67%Buy
PULM$7.00N/AN/A
OSRH$1.35N/AN/A
IGC$0.31$3.88+1,150.00%Strong Buy
TENX$5.85N/AN/A
View Top Biotech Stocks

Tempest Therapeutics Stock Forecast FAQ

Is Tempest Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TPST) stock is to Buy TPST stock.

Out of 2 analysts, 0 (0%) are recommending TPST as a Strong Buy, 1 (50%) are recommending TPST as a Buy, 1 (50%) are recommending TPST as a Hold, 0 (0%) are recommending TPST as a Sell, and 0 (0%) are recommending TPST as a Strong Sell.

If you're new to stock investing, here's how to buy Tempest Therapeutics stock.

What is TPST's earnings growth forecast for 2025-2027?

(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.31%.

Tempest Therapeutics's earnings in 2025 is -$44,799,000.On average, 2 Wall Street analysts forecast TPST's earnings for 2025 to be -$42,685,232, with the lowest TPST earnings forecast at -$47,061,430, and the highest TPST earnings forecast at -$38,308,667. On average, 1 Wall Street analyst forecast TPST's earnings for 2026 to be -$58,992,497, with the lowest TPST earnings forecast at -$58,992,497, and the highest TPST earnings forecast at -$58,992,497.

In 2027, TPST is forecast to generate -$49,086,765 in earnings, with the lowest earnings forecast at -$49,086,765 and the highest earnings forecast at -$49,086,765.

What is TPST's revenue growth forecast for 2028-2028?

(NASDAQ: TPST) Tempest Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.9%.

Tempest Therapeutics's revenue in 2025 is $0.

In 2028, TPST is forecast to generate $13,624,984 in revenue, with the lowest revenue forecast at $13,624,984 and the highest revenue forecast at $13,624,984.

What is TPST's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TPST) forecast ROA is -181.92%, which is lower than the forecast US Biotechnology industry average of 40.47%.

What is TPST's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TPST price target, the average TPST price target is $11.50, with the highest TPST stock price forecast at $16.00 and the lowest TPST stock price forecast at $7.00.

On average, Wall Street analysts predict that Tempest Therapeutics's share price could reach $11.50 by Apr 10, 2026. The average Tempest Therapeutics stock price prediction forecasts a potential upside of 66.67% from the current TPST share price of $6.90.

What is TPST's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TPST) Tempest Therapeutics's current Earnings Per Share (EPS) is -$17.98. On average, analysts forecast that TPST's EPS will be -$11.59 for 2025, with the lowest EPS forecast at -$12.78, and the highest EPS forecast at -$10.40. On average, analysts forecast that TPST's EPS will be -$16.02 for 2026, with the lowest EPS forecast at -$16.02, and the highest EPS forecast at -$16.02. In 2027, TPST's EPS is forecast to hit -$13.33 (min: -$13.33, max: -$13.33).

What is TPST's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TPST) forecast ROE is -525.59%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.